Search

Displaying results 5661 - 5670 of 7897 in total
  1. Drug

    AVN-944

    go.drugbank.com/drugs/DB05500
    Investigational

    AVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism

  2. Drug

    Nangibotide

    go.drugbank.com/drugs/DB16247
    Investigational

    Nangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).

  3. Drug

    Sage oil

    go.drugbank.com/drugs/DB11199
    ApprovedNutraceutical

    *Salvia officinalis* is a common sage and a member of the genus *Salvia*, that includes aromatic and perennial plants with flowers. … Essential oil has been traditionally used in medicine for the relief of pain and the treatment of inflammation and infections, as it is reported to exhibit carminative, antispasmodic, antiseptic, and astringent

  4. Drug

    XAV-19

    go.drugbank.com/drugs/DB15895
    Investigational

    As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384). … However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558].

  5. Drug

    Anti-SARS-CoV-2 IgY

    go.drugbank.com/drugs/DB16356
    Investigational

    Anti-SARS-CoV-2 IgY are chicken egg antibodies to SARS-CoV-2 which have the potential to provide temporary protection against the virus when administered as intranasal drops. … [L27381] To create these antibodies, chickens are injected in the chest with the spike protein, which is the surface protein of SARS-CoV-2; this results in an immune response mounted by the chickens towards

  6. Drug

    Rabeximod

    go.drugbank.com/drugs/DB05772
    Investigational

    Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.

  7. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  8. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  9. Drug

    Birtamimab

    go.drugbank.com/drugs/DB16414
    Investigational

    Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).

  10. Drug

    Cardiopet

    go.drugbank.com/drugs/DB18913
    Investigational

    Cardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).